Clinical trials
Amyloidosis clinical trials
Below are recruiting amyloidosis clinical trials, each written for real people, not researchers. We’re tracking 155 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06129656Recruiting
Cardiac Amyloidosis Registry at Leipzig Hospital
This study is a registry that collects information from people with cardiac amyloidosis. It helps doctors learn more about the condition and how to better treat it.
Leipzig, SaxonyAges Any age - NCT06158854RecruitingPhase 1/Phase 2
Study of etentamig (ABBV-383) for AL amyloidosis
This study tests a new drug called etentamig (ABBV-383) given through a vein to see if it can control disease activity in people with AL amyloidosis who have already tried other treatments. It may help if your disease has progressed or is not responding well to prior therapies.
Miami, FloridaAges 18 years+ - NCT06197165Recruiting
Shiatsu for amyloidosis symptoms and quality of life
This study tests whether shiatsu (a gentle Japanese touch therapy) can improve symptoms and quality of life for people with amyloidosis. If you have a bothersome symptom like pain, shortness of breath, or anxiety, this trial may help you feel better.
CréteilAges 18 years+ - NCT06205953Recruiting
European registry for newly diagnosed AL amyloidosis
This study collects information and samples from people newly diagnosed with AL amyloidosis who have not yet received treatment. It aims to improve how this rare disease is diagnosed and managed across Europe.
HeidelbergAges 18–99 - NCT06342466RecruitingPhase 2
Study of bortezomib, pomalidomide, and dexamethasone for AL amyloidosis
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
Beijing, Beijing MunicipalityAges 18–90 - NCT06376214Recruiting
Daratumumab for newly diagnosed light chain amyloidosis
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
Nanjing, JiangsuAges 18–75 - NCT06427304Recruiting
Heart scan study for amyloid protein in older adults
This trial is testing older adults with heart failure to see if a heart condition called cardiac amyloidosis (a buildup of abnormal protein in the heart) is present. If you are 80 or older, have been in the hospital for heart failure in the past year, and have a thickened heart wall, you may be able to join.
Paris, IIe-de-FranceAges 80 years+ - NCT06455748Recruiting
Daratumumab combo for new AL amyloidosis
This trial tests a combination of three drugs — daratumumab, pomalidomide, and dexamethasone — for people newly diagnosed with AL amyloidosis. The goal is to see if this treatment helps reduce the abnormal proteins and improve organ function.
Wenzhou, ZhejiangAges 18–80 - NCT06527521Recruiting
Checking for amyloidosis in trauma surgery patients
This study is looking for people having planned trauma surgery to see if they have a hidden condition called amyloidosis. It may help find the disease early, especially in people with certain health risks.
Sant Pere de Ribes, BarcelonaAges Any age - NCT06627309Recruiting
Rapid blood protein response and remission in AL amyloidosis
This trial is for people with AL amyloidosis who are being treated with daratumumab, bortezomib, and dexamethasone. It looks at how quickly a certain blood protein (called dFLC) drops after treatment starts and whether that predicts a complete remission.
Beijing, Beijing MunicipalityAges 18–99 - NCT06699394Recruiting
Teclistamab for AL amyloidosis after standard therapy
This trial tests an experimental drug, teclistamab, for people with a type of amyloidosis (AL) that has not improved with standard treatments. It aims to see if teclistamab can help when other treatments have not worked.
Beijing, Beijing MunicipalityAges Any age - NCT06790394RecruitingPhase 1
Test-Retest PET Scan Study for Heart Amyloidosis
This study uses a special PET scan tracer to see how consistent the images are in people with heart amyloidosis (a buildup of abnormal protein in the heart) and in people without the condition. The goal is to improve diagnosis and monitoring.
LondonAges 40 years+ - NCT06836011Recruiting
Heart valve leakage study in a type of amyloid heart disease
This study looks at how common and how serious heart valve leaks are in people with transthyretin amyloid cardiomyopathy (a condition where abnormal protein builds up in the heart). The goal is to better understand these leaks and how they affect long-term health.
Graz, StyriaAges 18 years+ - NCT06894290Recruiting
International heart disease registry for amyloidosis
This study collects information from people with a specific type of heart disease called cardiac amyloidosis (AL or ATTR type). By joining a registry, you help doctors learn more about these conditions and how to better treat them.
BrugesAges 18 years+ - NCT06907836Recruiting
Transthyretin cardiac amyloidosis in internal medicine
This study looks back at medical records of patients who were diagnosed with transthyretin cardiac amyloidosis (a type of protein buildup in the heart) while hospitalized in internal medicine at Strasbourg University Hospitals between 2013 and 2023. It aims to describe their health journey and outcomes.
StrasbourgAges 18 years+ - NCT06935162RecruitingPhase 2
Teclistamab for previously treated AL amyloidosis
This trial tests a new drug called teclistamab for people with AL amyloidosis whose disease has not responded well to previous treatments. It aims to see if the drug can help control the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06971380RecruitingPhase 2
CAR-T therapy for multiple myeloma and amyloidosis
This trial tests a new CAR-T cell treatment (HBI0101) for people with multiple myeloma or light-chain amyloidosis that has come back or stopped responding to other treatments. The therapy uses your own immune cells to fight cancer, and the goal is to see if it can help control the disease.
JerusalemAges 18 years+ - NCT06974877RecruitingPhase 1
PET/CT Imaging for Amyloid in CAPS on Anakinra
This trial uses a special PET/CT scan to see if a radioactive tracer can measure changes in amyloid buildup in people with CAPS who have developed a skin reaction to anakinra. It may help doctors understand how the disease is affecting your organs.
Bethesda, MarylandAges 18–120 - NCT06983951Recruiting
Study of CAR T cells for light chain amyloidosis
This trial tests a type of immunotherapy called CAR T cells that target a protein called BCMA on abnormal cells. It is for people whose light chain amyloidosis has come back or not responded to previous treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07079423RecruitingPhase 2
Teclistamab for new advanced AL amyloidosis
This trial tests a new drug called teclistamab for people newly diagnosed with advanced (stage IIIB) AL amyloidosis, a condition where abnormal proteins build up and damage organs. The goal is to see if teclistamab can help control the disease.
BeijingAges 18 years+ - NCT07130565Recruiting
Pan-Amyloid PET/CT Scan for Amyloid Heart Disease
This trial is testing a special PET/CT scan (Pan-Amyloid) that finds abnormal protein deposits (amyloid) in the heart and body. It is for people who have or may have cardiac amyloidosis and are already planning to get this scan.
Hefei, AnhuiAges 18–80 - NCT07154381Recruiting
Hybrid PET/MRI for heart amyloidosis imaging
This study uses a hybrid PET/MRI scanner to take detailed images of the heart in people with amyloidosis. The goal is to see how well this scan shows the buildup of amyloid protein, which could help doctors better diagnose and manage the condition.
Essen, North Rhine-WestphaliaAges 40 years+ - NCT07216469Recruiting
Heart Stiffness in Amyloidosis: A Study Using MRI
This study uses a special MRI scan to measure how stiff the heart muscle is in people with cardiac amyloidosis. The goal is to better understand the condition and potentially guide future treatments.
Rochester, MinnesotaAges 20 years+ - NCT07218705Recruiting
MCG scan study for cardiac amyloidosis
This study uses a new type of heart scan (MCG) to help understand cardiac amyloidosis. It may help doctors learn more about the condition without needing invasive tests.
Rochester, MinnesotaAges 18 years+
Hear when a new Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for amyloidosis?
- Yes. Clin2 currently lists 155 recruiting amyloidosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a amyloidosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a amyloidosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.